HOPKINS LUPUS COHORT: 1999 Update
Section snippets
EPIDEMIOLOGY OF LUPUS
The natural history of lupus has changed dramatically since the 1970s not only because of better treatments for systemic lupus erythematosus (SLE) but because of better supportive measures, including antibiotics, better management of coronary artery disease, renal dialysis, and renal transplantation. Lupus seems to have increased in its incidence and prevalence since the 1970s. In a landmark study done in Rochester, Minnesota, Uramoto et al36 found that the incidence of lupus has tripled in the
ENVIRONMENTAL TRIGGERS OF LUPUS
The remarkable increase in the incidence of SLE found in the Rochester, Minnesota study cannot be attributed to a change in the genetic background of the population. The author postulates that environmental triggers are increasing the incidence of SLE. The author examined several of these environmental triggers using nested case-control studies within the Hopkins Lupus Cohort. One of the first environmental triggers examined was hair dyes. Earlier studies had suggested that hair dyes might be a
DISEASE ACTIVITY
The Hopkins Lupus Cohort was the setting for the author's initial study of flare in SLE. The author defined flare using the Physician's Global Assessment as a gold standard. The Physician's Global Assessment has been part of the Hopkins Lupus Cohort assessments since the beginning of the cohort. On this 0 to 3 visual analog scale, a flare was defined as a change of 1.0 or greater happening within the last 3 months. The author picked 3 months simply for convenience, because most of the follow-up
EVOLUTION OF LUPUS
In addition to the fact that the majority of patients with SLE continue to have disease activity in either the flare or chronic active pattern, most patients with SLE show evolution of their lupus into new organ systems as time passes.25 This is different from the progression of SLE found in Europe as reported by Swaak et al,33 who rarely found that there was any evolution into new organ systems after 5 years of established disease. The author found the progression of lupus to occur in every
Raynaud's Phenomenon
Raynaud's phenomenon, although common in SLE, is not specific and is no longer included in the ACR classification criteria. The author investigated whether Raynaud's phenomenon was associated with SLE manifestations or with the later course of the disease. The author found that Raynaud's phenomenon was commonly associated with other cutaneous manifestations of lupus, including malar rash, discoid lupus, mouth ulcers, and alopecia. In addition, and surprisingly, Raynaud's phenomenon was
DAMAGE
There is consensus internationally that the ACR/SLICC Damage Index is the best instrument to measure damage in organ systems after the diagnosis of lupus. Musculoskeletal damage heads the list in our cohort, with 25% of patients with SLE affected. The musculoskeletal damage includes both avascular necrosis and osteoporosis with fractures. Overall, patients who have died have three or more organ systems damaged as opposed to patients who are living. Of our living patients, on average, 50% have
HEALTH STATUS
Multiple groups have used either the 20-item or 36-item Short-Form Health Survey38 to measure health status in patients with SLE. In general, the health status of patients with SLE using these instruments is poor. It is surprising that health status does not seem to be highly concordant with either disease activity or disease damage. There appear to be other predictors of health status.
The author has been interested in the high frequency of fibromyalgia that was found in the lupus cohort. Of
CONCLUSIONS
It is necessary to examine three domains—disease activity, damage and health status—to adequately describe SLE. Longitudinal cohort studies such as the Hopkins Lupus Cohort can address all three of these domains. Obviously, any single cohort cannot adequately or definitively answer all issues because of the differences in race, education, and other socioeconomic status variables between cohorts. Cohort studies that include well-characterized patients followed frequently over time can help in
References (41)
- et al.
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network
Kidney Int
(1997) - et al.
Fibromyalgia (FM) and disease activity in systemic lupus erythematosus: Role of race and socioeconomic status
Am J Med
(1991) - et al.
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
Am J Med
(1994) - et al.
Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status
Am J Med
(1991) - et al.
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
Lancet
(1996) - et al.
Risk factors for coronary artery disease in patients with systemic lupus erythematosus
Am J Med
(1992) - et al.
The bimodal mortality pattern of systemic lupus erythematosus
Am J Med
(1976) - et al.
Association of coping responses with fibromyalgia tender points in systemic lupus erythematosus patients [abstract]
Arthritis Rheum
(1997) - et al.
High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients
Nephrol Dial Transplant
(1995) - et al.
Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail
Arthritis Rheum
(1996)
Systemic lupus erythematosus in the community: Incidence, prevalence, outcome, and first symptoms; The high prevalence in black women
Arch Intern Med
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index for systemic lupus erythematosus
Arthritis Rheum
The ACR/SLICC Damage Index in systemic lupus erythematosus (SLE) [abstract]
Arthritis Rheum
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity
Arthritis Rheum
Age at onset of SLE affects disease manifestations and course [abstract]
Arthritis Rheum
The effect of education on the clinical manifestations and morbidity of systemic lupus erythematosus [abstract]
Arthritis Rheum
The effect of race on the presentation and course of SLE in the United States [abstract]
Arthritis Rheum
Male lupus differs from female lupus in presentation and outcome [abstract]
Arthritis Rheum
Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update
Arthritis Care and Research
Raynaud's phenomenon is strongly associated with cutaneous, musculoskeletal and neuropsychiatric lupus [abstract]
Arthritis Rheum
Cited by (123)
Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review
2023, Current Problems in CardiologyCitation Excerpt :Furthermore, atherosclerosis is a major problem in primary APS because it contributes to the cardiovascular mortality. In the Hopkins Lupus cohort, which included patients with SLE, the prevalence of AMI was 3.3% in patients with aPL positive SLE and 5.9% in patients with aPL negative SLE (P= 0.06), which led to the assumption that early atherosclerosis in SLE is not associated with autoantibodies including aPLs.28,29 Interestingly, in the study of Baron et.
Cardiac Involvement in Systemic Lupus Erythematosus
2017, Handbook of Systemic Autoimmune DiseasesA series of 115 patients with systemic lupus erythematosus: Clinical and immunological characteristics
2014, Revista Colombiana de Reumatologia
Address reprint requests to Michelle Petri, MD, MPH, Hopkins Lupus Cohort, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, e-mail: [email protected]
The Hopkins Lupus Cohort is supported by NIAMS AR 43727 and the Outpatient General Clinical Research Center RR 00052.
- *
Hopkins Lupus Cohort, Johns Hopkins University School of Medicine, Baltimore, Maryland